Overview
The production of Nerve Growth Factor (NGF) has largely moved from E. coli to mammalian cell systems (such as CHO or HEK293) primarily to overcome issues with protein folding, solubility, and post-translational modifications, ensuring a more active and stable therapeutic product. While E. coli is cheaper and faster, it often produces NGF in inactive, insoluble inclusion bodies that require complex, inefficient refolding steps.
Key Reasons for Moving to Mammalian Cells
Proper Folding and Functionality
NGF requires the formation of three crucial intra-chain disulfide bonds to be biologically active. Mammalian cells possess an endoplasmic reticulum (ER) that facilitates proper folding and disulfide bonding, whereas the reducing environment of E. coli cytoplasm is inappropriate for this.
Post-Translational Modifications (PTMs)
Mammalian cells can perform necessary PTMs like glycosylation, which affects protein stability and solubility. E. coli lacks the machinery to perform these modifications.
Solubility and Processing
While E. coli frequently produces NGF as insoluble inclusion bodies, mammalian cells can secrete correctly folded, soluble, and biologically active mature NGF into the growth medium.
Higher Potential Yields
While E. coli is fast, optimized mammalian cell lines (like HEK293/CHO) have demonstrated higher production capacities, with reports up to 173.1 mg/L, making them highly efficient for producing human-like proteins.
E. coli vs. Mammalian Cell Production
| Feature | E. coli | Mammalian Cells |
| Protein Folding | Inclusion bodies, requires refolding | Proper folding via ER machinery |
| Disulfide Bonds | Difficult (reducing environment) | Correct formation |
| PTMs | None | Glycosylation, others |
| Solubility | Low (inclusion bodies) | High (secreted) |
| Biological Activity | Variable (5-20% after refolding) | High (>90%) |
| Production Speed | Fast (hours to days) | Slower (days to weeks) |
| Cost | Low cultivation, high purification | High cultivation, simpler purification |
| Scalability | Excellent | Good (improving) |
| Best Use | Research-grade material | Therapeutic applications |
NGF Production in Bacteria (E. coli)
Methodology
Often produces mature β-NGF as inclusion bodies, requiring denaturation and in vitro refolding to obtain active proteins.
Yield & Cost
High yields and low-cost, rapid cultivation make it suitable for large-scale production, but requires expensive purification steps.
Disulfide Bonds
NGF requires three intra-chain disulfide bonds for stability and activity. E. coli’s reducing cytoplasm makes this difficult, often leading to inactive protein.
Solutions
Specialized engineered strains (e.g., E. coli Origami) and low-temperature induction (e.g., 32°C) can improve solubility.
Activity
With correct refolding protocols, bacterial NGF is biologically active and comparable to natural NGF in bioassays.
Limitations of E. coli for NGF Production
Folding Difficulties: The reduced environment of the E. coli cytoplasm is inappropriate for forming the three intrachain disulfide bonds required for biological activity, causing protein accumulation in inactive inclusion bodies.
Low Active Yields: Studies indicate that as little as 5% of the produced protein might be biologically active.
Process Complexity: Production requires labor-intensive extraction and renaturation (refolding) processes.
NGF Production in Mammalian Cells
Methodology
Secretion of soluble, fully folded, and biologically active, glycosylated NGF into the culture medium.
Advantages
Superior folding machinery and post-translational modifications (disulfide bond formation) ensure higher biological activity.
Yield & Cost
Generally lower yields, slower growth, and higher costs due to complex media and specialized equipment.
Applications
Preferred for therapeutic applications where complex folding and native structure are critical.
Transition to Mammalian Cells
Genentech and other researchers moved toward mammalian systems (like CHO or HEK293) for several key reasons:
Proper Folding and Secretion: Mammalian cells possess the necessary machinery to properly fold, modify, and secrete biologically active, mature human NGF.
Increased Biological Activity: Mammalian expression systems produce correctly folded, biologically active NGF that mimics the native protein.
Industrial Scalability: Despite higher initial costs, mammalian cells allow for high-density, scalable, and efficient production, with some systems achieving yields of 4 mg/L or higher.
The Genentech Era: Pioneering Work by Cori Gorman
Based on the pioneering work in recombinant protein expression, including that of Cori Gorman at Genentech in the 1980s and early 1990s, the production of Nerve Growth Factor (NGF) differs significantly between bacterial (E. coli) and mammalian (e.g., CHO cells) systems, primarily regarding protein folding, solubility, and post-translational processing.
Key Takeaways from Genentech Research
Cori Gorman’s work highlighted that while bacteria can produce high amounts of raw material, mammalian systems are superior for producing complex, biologically active proteins like NGF because they ensure correct folding and post-translational modification. Mammalian cells avoid the need for the arduous in vitro refolding required by bacterial, inclusion-body-based production.
Production in CHO/Mammalian Cells
Methodology: Mammalian cells (such as Chinese Hamster Ovary cells) are used to secrete soluble, properly folded, and active NGF into the culture medium.
Advantages: Mammalian systems provide the necessary machinery for post-translational modifications, proper disulfide bond formation, and correct processing of the pro-NGF precursor.
Results: Studies using CHO cells for human NGF produce high yields (e.g., 4 mg/L or higher) of fully bioactive, soluble, and dimeric NGF.
Processing: The protein is often secreted, simplifying purification and eliminating the need for complex refolding procedures.
Structural Biology: NGF and BDNF
Based on structural studies of neurotrophins, Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF) share significant structural homology, featuring a “dimer of dimers” structure. Both proteins consist of non-covalently linked homodimers, each with a characteristic shape, often described as having a central knot with three disulfide bridges (cystine knot) and extended, twisted beta-hairpins.
Structural Features
Dimeric Structure: Both NGF and BDNF are homodimers essential for binding their respective Trk receptors (TrkA for NGF, TrkB for BDNF).
Molecular Shape: The 3D structure resembles a “dimer of dimers” or, in complex with receptors, has a crab-like appearance.
Conserved Motifs: They share approximately 50% amino acid identity and both contain a conserved cystine knot motif formed by three disulfide bonds.
Key Differences
BDNF Structure: Has a more defined pro-region and mature domain, often depicted as a compact globular dimer.
NGF Structure: Defined by two long, distorted beta-hairpins and its interaction with the TrkA receptor.
Binding Affinity: While structurally similar, they are highly specific to their respective receptors, determined by specific amino acid sequences in their variable loops.
For detailed, high-resolution 3D images of the molecular structures (PDB files), you can refer to databases like RCSB PDB using the codes 1BND (BDNF) or 1BET (NGF).
Therapeutic Potential of NGF and BDNF
Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF) are potent neurotrophins holding promise as therapeutic agents for neurodegenerative diseases (Alzheimer’s, Parkinson’s) and depression due to their critical roles in neuronal survival, synaptic plasticity, and regeneration.
Alzheimer’s Disease (AD)
NGF supports cholinergic neurons, often the first affected in AD. BDNF is crucial for synaptic integrity and memory in the hippocampus. Studies show NGF gene delivery and BDNF supplementation can enhance cognitive function and reduce neurodegeneration in models.
Neuroprotection and Regeneration
Both factors support neuron survival and neurogenesis, making them potential disease-modifying treatments for diseases like Huntington’s and ALS.
Depression
BDNF has shown potential as a new antidepressant mechanism, with studies indicating it promotes neurogenesis, while NGF has shown antidepressant-like effects in chronic studies.
Limitations & Challenges
Drug Delivery: Full-sized neurotrophins are large proteins that cannot cross the blood-brain barrier, necessitating complex delivery methods.
Stability: They are unstable in biological fluids.
Side Effects: NGF can cause pain, as it is involved in pain signaling (e.g., in irritable bowel syndrome).
Current Research Directions
Research is focused on developing small molecule mimetics that can cross the blood-brain barrier and mimic the actions of BDNF and NGF on their receptors (TrkB for BDNF, TrkA for NGF).
Conclusion
While bacteria allow for rapid, high-yield production, the necessity of refolding NGF to fix improperly formed disulfide bonds can limit its total yield of active protein. Mammalian cells are generally more suitable for obtaining fully functional, therapeutic-grade NGF despite the higher cost and complexity.
Currently, mammalian cells are the preferred system for producing recombinant human NGF (rhNGF) due to superior quality, although E. coli is still used for research-grade materials due to its speed and low cost.
Key References
Bothwell M. (2014). NGF, BDNF, NT3, and NT4. Handbook of Experimental Pharmacology, 220, 3-15. doi: 10.1007/978-3-642-45106-5_1. PMID: 24668467
Huang EJ, Reichardt LF. (2001). Neurotrophins: roles in neuronal development and function. Annual Review of Neuroscience, 24, 677-736.
Gorman C, et al. Genentech pioneering work on recombinant protein expression in mammalian cells (1980s-1990s).